The Medical Letter - 2002
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Year:    Publication:     
January 7, 2002 (Issue 1121)  
January 21, 2002 (Issue 1122)  
February 4, 2002 (Issue 1123)  
  • Drugs for Non-HIV Viral Infections   
    Superseded by Treatment Guidelines "Antiviral Drugs" - Issue 127, March 1, 2013The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins...
February 18, 2002 (Issue 1124)  
March 4, 2002 (Issue 1125)  
March 18, 2002 (Issue 1126)  
April 1, 2002 (Issue 1127)  
April 15, 2002 (Issue 1128)  
  • Advice for Travelers   
    Superseded by The Medical Letter "Advice for Travelers" - Issue 1582, October 7, 2019Patients planning to travel to other countries often ask physicians for advice about immunizations and...
April 29, 2002 (Issue 1129)  
  • Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor   
    Valdecoxib (Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx), was recently approved by the FDA for...
  • Pantoprazole IV (Protonix IV)   
    An IV formulation of pantoprazole sodium (Protonix IV - Wyeth-Ayerst), a benzimidazole proton pump inhibitor (PPI), has been approved by the FDA for short-term treatment of Zollinger-Ellison...
  • Copyright Violations   
    The Medical Letter is a nonprofit organization supported entirely by subscription fees and sales of books, software and individual issues. We do not accept advertisements, grants, donations or...
May 13, 2002 (Issue 1130)  
May 27, 2002 (Issue 1131)  
June 10, 2002 (Issue 1132)  
  • Triptorelin Pamoate (Trelstar)   
    Two controlled-release formulations of triptorelin (trip toe rel' in) pamoate, an agonist analog of human luteinizing hormone-releasing hormone (LHRH), are now available in the US for parenteral...
  • Tazarotene (Tazorac) for Acne   
    Tazarotene (taz ar' oh teen, Tazorac - Allergan), an acetylinic retinoid marketed for treatment of psoriasis (Medical Letter 1997; 39:105), is also available as a 0.1% gel and cream for...
  • Arrhythmias From Droperidol?   
    The FDA has added a "black box" warning about the risks of QT prolongation and the potentially fatal torsades de pointes (TdP) ventricular tachycardia to the labeling of droperidol (Inapsine...
June 24, 2002 (Issue 1133)  
July 8, 2002 (Issue 1134)  
July 22, 2002 (Issue 1135)  
  • Voriconazole   
    Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by...
  • Fulvestrant (Faslodex) for Advanced Breast Cancer   
    Fulvestrant (Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive...
August 5, 2002 (Issue 1136)  
  • Alosetron (Lotronex) revisited   
    The FDA recently announced that it will permit reintroduction of alosetron hydrochloride (Lotronex - GlaxoSmithKline) for treatment of irritable bowel syndrome (IBS). The drug was previously...
  • Olmesartan (Benicar) for hypertension   
    Olmesartan medoxomil (Benicar - Sankyo), a substituted imidazole, is the seventh oral angiotensin II receptor blocker (ARB) approved by the FDA for treatment of hypertension.
August 19, 2002 (Issue 1137)  
  • Tests for Drugs of Abuse   
    Testing for drug use has become increasingly common, not only in health care, but also in drug rehabilitation, in the military, at the workplace, after accidents and in the criminal justice system....
  • Neotame - a new artificial sweetener   
    Neotame (Neotame - NutraSweet Co.), an analog of aspartame (NutraSweet, and others), has been approved by the FDA for use as a nonnutritive sweetener and "flavor enhancer" in foods and...
September 2, 2002 (Issue 1138)  
September 16, 2002 (Issue 1139)  
September 30, 2002 (Issue 1140)  
  • Escitalopram (Lexapro) for Depression   
    Escitalopram (Lexapro - Forest), the active S-enantiomer of racemic citalopram (Celexa - Forest), a selective serotonin reuptake inhibitor (SSRI), was recently approved by the FDA for...
  • Problems With Dietary Supplements   
    Millions of people now take herbal products and other "dietary supplements." The Physicians' Desk Reference has published a PDR for Herbal Medicines listing their ingredients and indications, and...
October 14, 2002 (Issue 1141)  
  • Once-a-week Risedronate (Actonel)   
    A once-weekly 35-mg oral formulation of the bisphosphonate risedronate (Actonel) has been approved by the FDA for prevention and treatment of postmenopausal osteoporosis. A once-weekly...
  • Beta Interferons for Multiple Sclerosis   
    Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
  • Generic drugs   
    When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent...
October 28, 2002 (Issue 1142)  
  • Acetaminophen Safety   
    An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen (www.fda.gov, search "acetaminophen hepatotoxicity").
  • Drugs Past Their Expiration Date   
    Superseded by The Medical Letter "Drugs Past Their Expiration Date" - Issue 1483, December 7, 2015Physicians and pharmacists are often asked if patients can use drugs after their expiration...
November 11, 2002 (Issue 1143)  
November 25, 2002 (Issue 1144)  
December 9, 2002 (Issue 1145)  
December 23, 2002 (Issue 1146)